Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference27 articles.
1. Public Health Agency of Canada. Dementia in Canada, including Alzheimer’s disease highlights from the Canadian chronic disease surveillance system, Ottawa, Canada. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/dementia-highlights-canadian-chronic-disease-surveillance/dementia-highlights-canadian-chronic-disease-surveillance.pdf. Accessed 11 Jul 2020.
2. Canadian Institute of Health Information. Use of antipsychotics among seniors living in long-term care facilities, Canada. Available from: https://secure.cihi.ca/free_products/LTC_AiB_v2_19_EN_web.pdf. Accessed 11 July 2020.
3. Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The american psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–6.
4. Deyn PPD, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19(2):115–26.
5. Street JS, Clark SW, Gannon KS. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry. 2000;57(10):968.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献